JEUVEAU (prabotulinumtoxina-xvfs)
JEUVEAU (prabotulinumtoxinA-xvfs) is a neuromuscular blocking agent and acetylcholine release inhibitor. It is indicated for adult patients to achieve temporary improvement in the appearance of moderate to severe glabellar lines. The treatment specifically addresses lines associated with the activity of the corrugator and procerus muscles. By reducing localized muscle activity, the drug provides a temporary aesthetic modification for these facial features.
How JEUVEAU Works
JEUVEAU blocks neuromuscular transmission by binding to motor nerve terminals and inhibiting the release of acetylcholine. This inhibition is achieved by cleaving SNAP-25, a protein essential for the docking and release of acetylcholine from nerve ending vesicles. Intramuscular injection produces partial chemical denervation, resulting in a localized reduction in muscle activity. The effect is eventually reversed as reinnervation of the muscle occurs.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2019-02-01
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
JEUVEAU Approval History
What JEUVEAU Treats
1 indicationsJEUVEAU is approved for 1 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Glabellar Lines
JEUVEAU Boxed Warning
DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines. [ See Warnings and Precautions ( 5.1 )...
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines. [ See Warnings and Precautions ( 5.1 ) ] WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines. ( 5.1 )
JEUVEAU Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to JEUVEAU
3 of 4FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06903975 | H-45473 | Ph 4 | recruiting | BoTox Into the Sternocleidomastoid Muscles (SCM) |
| NCT06604832 | KDEJ24 | Ph 1 | completed | Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture |
| NCT05320393 results posted | EVOLUS-CLIN201 | Ph 2 | completed | Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
JEUVEAU FDA Label Details
Indications & Usage
FDA Label (PDF)JEUVEAU is indicated for the treatment of Glabellar Lines.
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing diffic...
Track JEUVEAU with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment